JAK2 and acute lymphoblastic leukemia: Strikingly, Chang et al. (2021) demonstrated significant reductions in leukaemic burden in vivo CRLF2r ALL models treated with JAK2 PROTACS, but not ruxolitinib monotherapy (Chang et al., 2021).